Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
The new year can be challenging for finding financial assistance for pulmonary hypertension (PH) medications. Although charitable assistance foundations with PH funds currently are closed, other avenues for assistance are available. Visit the Pulmonary Hypertension Association’s financial assistance page for more information.
Pulmonary hypertension (PH) health professionals can meet the primary author of recently released PH guidelines at the PH Professional Network Symposium. Dr. Marc Humbert will discuss the new PH guidelines during the Sept. 28-30 PHA event in Arlington, Virginia. The guidelines, developed by a taskforce from the European Society of Cardiology and European Respiratory Society, were published in August 2022.
The Pulmonary Hypertension Association added three new courses on Genetics and PH to its Online University. Watch the videos to earn 2.75 continuing education credits.
While the world seems to have moved on from the pandemic, many in the pulmonary hypertension community are trying to catch up. Because PH makes people more vulnerable to serious COVID side effects, the community remains cautious about how to proceed. This year, the Pulmonary Hypertension Association wants to help you transition from pandemic mode to more familiar routines.
The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.
The Pulmonary Hypertension Association seeks empathetic volunteers eager to support their peers in the pulmonary hypertension community. As the year begins, we have several volunteer shifts for our in-person, phone and online support services. Tiffany Gunville of Minot, North Dakota, encourages others to get involved. “Others were there for me. Now it’s my turn to give back.”
Pulmovant is enrolling participants in its Phase 3 mosliciguat study after positive Phase 2 results.
The FDA will review United Therapeutic’s new drug application for Ralinepag, a once-daily pill to treat PAH.
Study suggests transdermal delivery could be alternative to existing treprostinil administration methods.
